The Debatable Benefit of Gross-Total Resection of Brain Metastases in a Comprehensive Treatment Setting
- PMID: 33801110
- PMCID: PMC8004079
- DOI: 10.3390/cancers13061435
The Debatable Benefit of Gross-Total Resection of Brain Metastases in a Comprehensive Treatment Setting
Abstract
Background and Purpose: The value of gross-total surgical resection remains debatable in patients with brain metastases (BMs) as most patients succumb to systemic disease progression. In this study, we evaluated the impact of the extent of resection of singular/solitary BM on in-brain recurrence (iBR), focusing on local recurrence (LR) and overall survival (OS) in an interdisciplinary adjuvant treatment setting. Patients and Methods: In this monocentric retrospective analysis, we included patients receiving surgery of one BM and subsequent adjuvant treatment. A radiologist and a neurosurgeon determined in consensus the extent of resection based on magnetic resonance imaging. The OS was calculated using Kaplan-Meier estimates; prognostic factors for LR and OS were analysed by Log rank test and Cox proportional hazards. Results: We analyzed 197 patients. Gross-total resection was achieved in 123 (62.4%) patients. All patients were treated with adjuvant radiotherapy, and 130 (66.0%) received systemic treatment. Ninety-six (48.7%) patients showed iBR with an LR rate of 23.4%. LR was not significantly influenced by the extent of resection (p = 0.139) or any other parameter. The median OS after surgery was 18 (95%CI 12.5-23.5) months. In univariate analysis, the extent of resection did not influence OS (p = 0.6759), as opposed to adjuvant systemic treatment (p < 0.0001) and controlled systemic disease (p = 0.039). Systemic treatment and controlled disease status remained independent factors for OS (p < 0.0001 and p = 0.009, respectively). Conclusions: In this study, the extent of resection of BMs neither influenced the LR nor the OS of patients receiving interdisciplinary adjuvant treatment.
Keywords: brain metastasis; comprehensive oncological treatment; extent of resection; systemic treatment.
Conflict of interest statement
The authors declare that they have no conflict of interest.
Figures


Similar articles
-
Resection of symptomatic non-small cell lung cancer brain metastasis in the setting of multiple brain metastases.J Neurosurg. 2021 Oct 29;136(6):1576-1582. doi: 10.3171/2021.7.JNS211172. Print 2022 Jun 1. J Neurosurg. 2021. PMID: 34715653
-
Single brain metastases - prognostic factors and impact of residual tumor burden on overall survival.Front Oncol. 2024 Mar 15;14:1330492. doi: 10.3389/fonc.2024.1330492. eCollection 2024. Front Oncol. 2024. PMID: 38559561 Free PMC article.
-
Impact of regular magnetic resonance imaging follow-up after stereotactic radiotherapy to the surgical cavity in patients with one to three brain metastases.Radiat Oncol. 2019 Mar 14;14(1):45. doi: 10.1186/s13014-019-1252-x. Radiat Oncol. 2019. PMID: 30871597 Free PMC article. Clinical Trial.
-
Synovial sarcoma in children: surgical lessons from a single institution and review of the literature.J Am Coll Surg. 2001 Mar;192(3):305-13. doi: 10.1016/s1072-7515(00)00806-1. J Am Coll Surg. 2001. PMID: 11245372 Review.
-
Supratentorial hemispheric ependymomas: an analysis of 109 adults for survival and prognostic factors.J Neurosurg. 2016 Aug;125(2):410-8. doi: 10.3171/2015.7.JNS151187. Epub 2016 Jan 8. J Neurosurg. 2016. PMID: 26745489 Review.
Cited by
-
Prognostic factors following resection of intracranial metastases.Surg Neurol Int. 2022 May 27;13:219. doi: 10.25259/SNI_103_2022. eCollection 2022. Surg Neurol Int. 2022. PMID: 35673669 Free PMC article.
-
Reconsideration of the resection strategy of eloquent brain metastasis in the era of postoperative stereotactic radiotherapy: a comparative analysis with non-eloquent metastasis.J Neurooncol. 2025 Sep;174(2):439-448. doi: 10.1007/s11060-025-05075-0. Epub 2025 May 23. J Neurooncol. 2025. PMID: 40408062 Free PMC article.
-
Role of microsurgical tumor burden reduction in patients with breast cancer brain metastases considering molecular subtypes: a two-center volumetric survival analysis.J Neurooncol. 2024 Sep;169(2):379-390. doi: 10.1007/s11060-024-04728-w. Epub 2024 Jun 3. J Neurooncol. 2024. PMID: 38829577 Free PMC article.
-
Neurosurgical resection of multiple brain metastases: outcomes, complications, and survival rates in a retrospective analysis.J Neurooncol. 2024 Sep;169(2):349-358. doi: 10.1007/s11060-024-04744-w. Epub 2024 Jun 21. J Neurooncol. 2024. PMID: 38904924 Free PMC article.
-
Epidemiology and palliative care of in-patient cerebral metastases cases in Germany.J Neurooncol. 2025 May;173(1):37-48. doi: 10.1007/s11060-024-04928-4. Epub 2025 Apr 11. J Neurooncol. 2025. PMID: 40214907 Free PMC article.
References
-
- Tabouret E., Chinot O., Metellus P., Tallet A., Viens P., Gonçalves A. Recent Trends in Epidemiology of Brain Metastases: An Overview. Anticancer Res. 2012;32:4655–4662. - PubMed
-
- Vecht C.J., Haaxma-Reiche H., Noordijk E.M., Padberg G.W., Voormolen J.H.C., Hoekstra F.H., Tans J.T.J., Lambooij N., Metsaars J.A.L., Wattendorff A.R., et al. Treatment of Single Brain Metastasis: Radiotherapy Alone or Combined with Neurosurgery. Ann. Neurol. 1993;33:583–590. doi: 10.1002/ana.410330605. - DOI - PubMed
LinkOut - more resources
Full Text Sources
Other Literature Sources